In prostate cancer specifically, CD166-positive cells have enhanced sphere-forming capacity and carcinogenic potential (55), while in breast cancer, CD166 promotes evasion of apoptosis of the cancer cells (56). Here, ALCAM is linked to prostate carcinoma.